Vinita Gupta, 

In the early 2000s, Gupta was tasked with building Lupin’s U.S. business, which now accounts for about 35%-40% of the company’s overall business. Lupin has emerged as the third largest generic pharmaceuticals company in the U.S., delivering over 17 billion doses of medication per year. Gupta has now turned her sights on the larger global business portfolio of the company. In the last year, Lupin divested its operations in Japan and was able to net a post-tax gain of ₹1,124.5 crore.